Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
6.44
-0.11 (-1.68%)
May 18, 2026, 4:00 PM EDT - Market closed

Gyre Therapeutics Revenue

Gyre Therapeutics had revenue of $22.52M in the quarter ending March 31, 2026, with 2.09% growth. This brings the company's revenue in the last twelve months to $117.05M, up 16.30% year-over-year. In the year 2025, Gyre Therapeutics had annual revenue of $116.59M with 10.24% growth.

Revenue (ttm)
$117.05M
Revenue Growth
+16.30%
P/S Ratio
5.03
Revenue / Employee
$187,278
Employees
625
Market Cap
588.44M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2025116.59M10.83M10.24%
Dec 31, 2024105.76M-7.69M-6.78%
Dec 31, 2023113.45M11.16M10.91%
Dec 31, 2022102.29M94.95M1,293.98%
Dec 31, 20217.34M-34.56M-82.49%
Dec 31, 202041.90M--
Dec 31, 2019---
Dec 31, 20186.00K-1.01M-99.41%
Dec 31, 20171.02M619.00K155.14%
Dec 31, 2016399.00K-1.35M-77.20%
Dec 31, 20151.75M-63.00K-3.47%
Dec 31, 20141.81M1.29M246.65%
Dec 31, 2013523.00K-115.20M-99.55%
Dec 31, 2012115.72M-79.55M-40.74%
Dec 31, 2011195.27M23.85M13.91%
Dec 31, 2010171.43M121.30M242.00%
Dec 31, 200950.12M9.95M24.78%
Dec 31, 200840.17M17.02M73.51%
Dec 31, 200723.15M-31.92M-57.96%
Dec 31, 200655.07M52.71M2,233.81%
Dec 31, 20052.36M--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
CorMedix400.05M
Valneva SE180.25M
Zevra Therapeutics122.29M
Sutro Biopharma99.61M
Arvinas89.40M
Aclaris Therapeutics8.37M
Altimmune36.00K
Revenue Rankings